All In Biotech

Free tool

FAERS Monitor: Omidria

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205388 or its brand name (Omidria, Ketorolac Tromethamine, Phenylephrine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

82

Serious

47

57% of reports

Hospitalization

2

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • endophthalmitis19
  • toxic anterior segment syndrome17
  • corneal oedema15
  • anterior chamber inflammation5
  • corneal opacity4
  • fibrin4
  • hypopyon4
  • iritis4
  • keratitis4
  • uveitis4
  • vitritis4
  • anterior chamber disorder3
  • drug effect prolonged3
  • intraocular pressure increased3
  • pain3

Reports by year received

View as table
YearReports
20151
201618
201716
20186
20196
20208
20216
20223
20239
20241
20258

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,077 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
fibrinSignal426334.19629.773,140
toxic anterior segment syndromeSignal174064.12650.564,042
anterior chamber disorderSignal33393.31109.06,972
anterior chamber inflammationSignal52175.9927.08,730
corneal oedemaSignal151728.61092.024,041
drug effect prolongedSignal31403.0460.62,902
hypopyonSignal41246.4478.13,792
endophthalmitisSignal19815.0549.114,601
corneal opacitySignal4754.1289.52,296
vitritisSignal4555.5213.31,691
iritisSignal4337.9129.91,027
keratitisSignal4337.9129.91,027
uveitisSignal475.729.1225
intraocular pressure increasedSignal360.219.8121
pain31.30.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.